Navigation Links
Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
Date:5/7/2008

s

Forest Laboratories is a US-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in people's lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation; and Bystolic(TM) (nebivolol), a beta-adrenergic receptor blocking agent indicated for the treatment of hypertension. In addition to our growing product line, Forest also co-promotes the Daiichi Sankyo, Inc. product Azor(TM)* (amlodipine and olmesartan medoxomil), a calcium channel blocker and angiotensin receptor blocker combination product indicated for the treatment of hypertension. For more information, visit http://www.frx.com.

* Azor is a trademark of Daiichi Sankyo, Inc. and Campral is a registered trademark of Merck Sante s.a.s., a subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
2. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
3. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
6. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... YORK , Dec. 17, 2014 ... imaging (MRI), the MRI market is seeing new ... and breast MRI scans account for the majority ... a higher resolution of images, which are creating opportunities ... imaging (MRI) market is growing at a rate ...
(Date:12/17/2014)... MILAN , December 17, 2014 ... becoming nothing less than a hub of information concerning the ... A further addition to the recently launched ... world and has now been enriched by a new chapter ... A richly detailed and panoramic hub on ...
(Date:12/17/2014)... 17, 2014  IGI Laboratories, Inc. (NYSE MKT: IG; ... its offering of $125 million aggregate principal amount of ... Notes were offered and sold only to qualified institutional ... of 1933, as amended (the "Securities Act"). ... 3.75% per year, payable semiannually in arrears on June ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... ROCKVILLE, Md., Jan. 31, 2011 To further its ... manufacturers, the U.S. Pharmacopeial Convention (USP) has appointed Mr. ... Sao Paulo, Brazil facility. USP is a scientific nonprofit ... people around the world through standards and related programs ...
... 31, 2011 Global Real Estate Consultants has helped ... new facility in Fremont. Global Real ... insight and transparency in the Fremont commercial real estate ... 350,000 sq. ft. state-of-the-art manufacturing facility with pilot plant ...
Cached Medicine Technology:New Interim Leadership for USP-Brazil 2Boehringer Ingelheim to Purchase Amgen's Fremont (USA) Facility 2
(Date:12/19/2014)... 19, 2014 SuperCloset raises the bar ... SuperCloset continues to offer indoor growers the most efficient ... the new SuperClone Rooms with the award winning ... indoor hydroponic grow room setup. , The SuperClone Room ... SuperPonic SuperCloner 50 . The SuperClone ...
(Date:12/19/2014)... December 20, 2014 The Medspa at ... injectable filler from respected cosmetic brand Juvéderm. Voluma XC ... with age. The Medspa at Hendrick is pleased to ... skin care technology to its clients. , Voluma is ... be FDA-approved to treat the mid-face and cheek area. ...
(Date:12/19/2014)... 2014 (HealthDay News) -- All children should have their ... preferably every year, eye experts say. The new ... panel of the U.S. National Center for Children,s Vision ... age group require screening for eye problems, particularly vision ... amblyopia ("lazy eye") and strabismus (a disorder of eye ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- The cost of cancer ... a new study finds. Researchers examined data from ... diagnosed with colorectal or lung cancer. Of those patients, ... and more than 100 had advanced cancer. Nearly ... pay their medical bills, which was linked with a ...
(Date:12/19/2014)... Dennis Thompson HealthDay Reporter ... Ebola,s entrance into the United States -- along with ... outbreak -- have highlighted cracks in the nation,s public ... health policy report released Thursday. Half of U.S. ... to infectious disease outbreaks. That was the main conclusion ...
Breaking Medicine News(10 mins):Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4
... NEW YORK, Oct. 9 You may not ... if, according to health experts, you get your ... vaccinated against the virus that causes,36,000 deaths annually. ... http://media.medialink.com/WebNR.aspx?story=33948 Registered journalists can access video, ...
... ANGELES, Oct. 9 Elvira, Mistress of the,Dark, will ... dance party fundraiser benefiting AIDS Healthcare Foundation.,This wicked-cool event ... thrift,store in Hollywood at 6210 West Sunset Blvd. on ... 2007, will feature a fashion show and contest,highlighting the ...
... Tissue Donor Registry Reaches 2 ... Million Registrations ... SACRAMENTO, Calif., Oct. 9 More than two million,Californians have signed up ... & Tissue Donor Registry, doubling the,state,s number of designated donors in only ...
... House Republican Whip Roy,Blunt (Mo.) issued the following ... yesterday suggested on CNN that Democrats wouldn,t,be able ... veto of the,SCHIP bill:, "Yesterday, the House ... override the president,s veto of a bill that ...
... crossword-puzzle solver who uses the letters in some answers ... and an international group of collaborators have used data ... to identify a gene linked to non-hereditary cases of ... posted online by the journal Nature Genetics, didnt require ...
... Actor Joe Pantoliano,reveals a personal history of depression ... bipolar disorder, in a guest blog entry, http://www.nami.org/blog ... Mental,Illness (NAMI)., Pantoliano,s entry comes during Mental ... before the opening of his latest film, CANVAS, ...
Cached Medicine News:Health News:'Something Wicked!' This Way Comes: Elvira Hosts Halloween Fashion Show and Fundraiser Benefiting AIDS Healthcare Foundation 2Health News:Two Million Californians Say 'Yes!' to Organ and Tissue Donation 2Health News:Two Million Californians Say 'Yes!' to Organ and Tissue Donation 3Health News:Two Million Californians Say 'Yes!' to Organ and Tissue Donation 4Health News:'Network' approach identifies potential breast cancer susceptibility gene 2Health News:'Network' approach identifies potential breast cancer susceptibility gene 3Health News:'Network' approach identifies potential breast cancer susceptibility gene 4Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2
... based on SIREMOBIL Iso-C, the first truly ... intra-operative 3D-Mode, the 3D-dataset is immediately available ... movement. This allows the surgeon to perform ... the procedure. This 3D capability is especially ...
... restricted to small central fields, unconventional ... full field capable, all encompassing systems ... ever need to ensure the most ... also include the most important and ...
... II-i series is a wheelchair accessible, computerized ... field. ,By using SITA, the expert operating ... up to 70%. ,A patented aspherically shaped ... increase patient comfort while testing out to ...
... results. The Kowa AP-340 a new concept ... system of ultimate simplicity. Quick, comfortable procedure ... a compact, unique design profile weighing just ... features.The integration of CRT display and instrumentation ...
Medicine Products: